Improving clinical practice with an old friend from the neuroimmunology toolkit: acute corticosteroids in LGI1 antibody encephalitis

Improving clinical practice with an old friend from the neuroimmunology toolkit: acute corticosteroids in LGI1 antibody encephalitis

Bibliografische gegevens
Hoofdauteur:	Irani, SR
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	BMJ Publishing Group 2021

Gelijkaardige items

Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis.
door: Tofaris, G, et al.
Gepubliceerd in: (2012)

LGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis
door: Jang, Y, et al.
Gepubliceerd in: (2018)

Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis.
door: Irani, SR, et al.
Gepubliceerd in: (2011)

LGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis
door: Yoonhyuk Jang, et al.
Gepubliceerd in: (2018-09-01)

Intrathecal B cell activation in LGI1-antibody encephalitis
door: Lehmann-Horn, K, et al.
Gepubliceerd in: (2020)

Clonal hematopoiesis in LGI1‐antibody encephalitis
door: Soo Jean Shin, et al.
Gepubliceerd in: (2024-10-01)

Clinical diagnosis of LGI1 antibody encephalitis in an 83-year-old woman
door: Attwood, JE, et al.
Gepubliceerd in: (2021)

Magnetic resonance imaging characteristics of LGI1-antibody and CASPR2-antibody encephalitis
door: Kelly, MJ, et al.
Gepubliceerd in: (2024)

Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?
door: Irani, SR, et al.
Gepubliceerd in: (2011)

LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures
door: Aurangzeb, S, et al.
Gepubliceerd in: (2017)

Antibody Properties Associate with Clinical Phenotype in LGI1 Encephalitis
door: Susann Ludewig, et al.
Gepubliceerd in: (2023-01-01)

Functional and Structural Brain Alterations in Encephalitis With LGI1 Antibodies
door: Jianping Qiao, et al.
Gepubliceerd in: (2020-04-01)

Autoimmune Encephalitis: An Expanding Frontier of Neuroimmunology
door: Hong-Zhi Guan, et al.
Gepubliceerd in: (2016-01-01)

Pathognomonic seizures in limbic encephalitis associated with anti-LGI1 antibodies.
door: Sen, A, et al.
Gepubliceerd in: (2014)

The immunogenetics of LGI1- and CASPR2-antibody encephalitis: towards aetiology
door: Binks, S
Gepubliceerd in: (2022)

The distinct pattern of movement disorders in Caspr2 and LGI1 antibody associated autoimmune encephalitis
door: Goevert, F, et al.
Gepubliceerd in: (2019)

Evaluation of LGI1-antibody Encephalitis, a Rare Cause of Limbic Encephalitis, from Diagnosis to Treatment
door: Halil İbrahim Uslusoy, et al.
Gepubliceerd in: (2022-06-01)

Psychiatric Manifestation of Anti-LGI1 Encephalitis
door: Dominique Endres, et al.
Gepubliceerd in: (2020-06-01)

Anti-LGI1 antibody autoimmune encephalitis. Clinical case presentation and literature review
door: A. Stašaitytė, et al.
Gepubliceerd in: (2021-03-01)

CSF Findings in Chinese Patients with NMDAR, LGI1 and GABABR Antibody-Associated Encephalitis
door: Qiao S, et al.
Gepubliceerd in: (2024-03-01)

Fire acupuncture for anti-LGI1 antibody autoimmune encephalitis: a case report
door: Yu Liu, et al.
Gepubliceerd in: (2023-07-01)

A case report of recurrent and MRI negative LGI1 antibody-associated encephalitis
door: Liu Tong, Xia Liping, Jia Yuqin
Gepubliceerd in: (2023-04-01)

CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis
door: Gelfand, JM, et al.
Gepubliceerd in: (2022)

Neuroimmunology in clinical practice /
door: Kalman, Bernadette, et al.
Gepubliceerd in: (2008)

NMDA receptor antibody related encephalitis
door: Irani, SR
Gepubliceerd in: (2012)

LGI1 encephalitis: Autoimmune epilepsy or movement disorder
door: Sujit A Jagtap, et al.
Gepubliceerd in: (2023-01-01)

A Case of LGI1 Encephalitis Presenting with NORSE
door: Gökberk Metin, et al.
Gepubliceerd in: (2024-03-01)

Pilomotor Seizures in a Patient With LGI1 Encephalitis
door: Jinxia Yang, et al.
Gepubliceerd in: (2020-02-01)

NMDA receptor antibody encephalitis.
door: Irani, SR, et al.
Gepubliceerd in: (2011)

A rare case of anti-LGI1 limbic encephalitis with concomitant positive NMDAR antibodies
door: Tuo Ji, et al.
Gepubliceerd in: (2020-09-01)

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
door: Lee, S, et al.
Gepubliceerd in: (2024)

Anti-LGI1 encephalitis with initiating symptom of seizures in children
door: Yang Wang, et al.
Gepubliceerd in: (2023-04-01)

Comparative effects of domain-specific human monoclonal antibodies against LGI1 on neuronal excitability
door: Sell, J, et al.
Gepubliceerd in: (2023)

Case report: Seropositive myasthenia gravis complicated by limbic encephalitis positive for antibodies to AMPAR and Lgi1
door: Magne Solberg Nes, et al.
Gepubliceerd in: (2023-10-01)

Clinical Characteristics of Cognitive Impairment and 1-Year Outcome in Patients With Anti-LGI1 Antibody Encephalitis
door: Hai-lun Hang, et al.
Gepubliceerd in: (2020-08-01)

Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study
door: Weishuai Li, et al.
Gepubliceerd in: (2018-07-01)

LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes
door: Binks, S, et al.
Gepubliceerd in: (2017)

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
door: Soon-Tae Lee, et al.
Gepubliceerd in: (2024-08-01)

Distinct HLA associations of LGI1 and CASPR2-antibody diseases
door: Binks, S, et al.
Gepubliceerd in: (2018)

EEG-confirmed epileptic activity in a cat with VGKC-complex/LGI1 antibody-associated limbic encephalitis.
door: Pakozdy, A, et al.
Gepubliceerd in: (2014)